The expression of Major Histocompatibility Complex class II (MHC II) molecules on tumour cells has emerged as a critical determinant of antitumour immunity. Conventionally restricted to professional ...
Tumor miRNA expression as a potential biomarker of immune-related toxicity in patients with melanoma or urothelial carcinoma treated with immune checkpoint inhibitors. This is an ASCO Meeting Abstract ...
Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results